For research use only. Not for therapeutic Use.
Bemfivastatin(CAT: I008832) (also known as PPD 10558) is an orally active HMG-CoA reductase inhibitor, classified within the statin family of lipid-lowering agents. It functions by inhibiting the enzyme HMG-CoA reductase, thereby reducing cholesterol synthesis in the liver. Notably, Bemfivastatin has been observed to enhance liver extraction activity. Toxicological studies indicate minimal developmental toxicity in pregnant rats and rabbits during organogenesis, with no observed adverse effect levels (NOAEL) of ≥320 mg/kg/day for rat developmental toxicity, 12.5 mg/kg/day for rabbit maternal toxicity, and 25 mg/kg/day for rabbit developmental toxicity. These findings suggest its potential utility in research focused on statin-related hypercholesterolemic myalgia, particularly in patients who are statin-intolerant.
| Catalog Number | I008832 |
| CAS Number | 805241-79-6 |
| Synonyms | (3R,5R)-7-[2-(4-fluorophenyl)-4-[[4-(hydroxymethyl)phenyl]carbamoyl]-3-phenyl-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid |
| Molecular Formula | C34H37FN2O6 |
| Purity | ≥95% |
| IUPAC Name | (3R,5R)-7-[2-(4-fluorophenyl)-4-[[4-(hydroxymethyl)phenyl]carbamoyl]-3-phenyl-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid |
| InChI | InChI=1S/C34H37FN2O6/c1-21(2)32-31(34(43)36-26-14-8-22(20-38)9-15-26)30(23-6-4-3-5-7-23)33(24-10-12-25(35)13-11-24)37(32)17-16-27(39)18-28(40)19-29(41)42/h3-15,21,27-28,38-40H,16-20H2,1-2H3,(H,36,43)(H,41,42)/t27-,28-/m1/s1 |
| InChIKey | PMFRPLBQEYHUMG-VSGBNLITSA-N |
| SMILES | CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=C(C=C4)CO |
